Culture Media MarketSize, Share & Industry Analysis, 2026-2034By Product TypeBy FormulationBy ApplicationBy Cell and Organism TypeBy Physical FormBy Media FunctionBy Packaging FormatBy Production ScaleBy End UserBy Distribution Channel
Full title & scope — all 10 axes with their segments
Culture Media Market Size, Share & Industry Analysis, By Product Type (Dehydrated Culture Media, Ready-to-Use Media, Media Supplements and Additives, Sera, Custom Media), By Formulation (Serum-Containing Media, Serum-Free Media, Chemically Defined Media, Protein-Free Media, Animal-Origin-Free Media), By Application (Biopharmaceutical Production, Cell and Gene Therapy, Clinical Microbiology Diagnostics, Pharmaceutical Quality Control, Food and Beverage Safety Testing, Environmental and Water Testing, Academic and Basic Research), By Cell and Organism Type (Bacterial, Fungal and Yeast, Mammalian, Insect, Stem Cells, Plant and Algae), By Physical Form (Powder, Liquid, Semi-Solid Gel, Lyophilized and Tablet), By Media Function (General-Purpose, Selective, Differential, Enrichment, Chromogenic, Transport), By Packaging Format (Petri Plates, Tubes and Vials, Bottles, Bags and Bioprocess Containers, Bulk Drums and Sacks), By Production Scale (Research Scale, Process Development Scale, Commercial Manufacturing Scale), By End User (Pharmaceutical and Biotechnology Companies, Contract Research and Manufacturing Organizations, Diagnostic Laboratories and Hospitals, Food and Beverage Manufacturers, Academic and Research Institutes), By Distribution Channel (Direct Sales, Distributors, Online and E-Commerce), and Regional Forecast, 2026-2034
Market outlook, key takeaways, drivers and challenges for the report period.
- 01By Product TypeDehydrated Culture Media · Ready-to-Use Media · Media Supplements and Additives
- 02By FormulationSerum-Containing Media · Serum-Free Media · Chemically Defined Media
- 03By ApplicationBiopharmaceutical Production · Cell and Gene Therapy · Clinical Microbiology Diagnostics
- 04By Cell and Organism TypeBacterial · Fungal and Yeast · Mammalian
- 05By Physical FormPowder · Liquid · Semi-Solid Gel
- 06By Media FunctionGeneral-Purpose · Selective · Differential
- 07By Packaging FormatPetri Plates · Tubes and Vials · Bottles
- 08By Production ScaleResearch Scale · Process Development Scale · Commercial Manufacturing Scale
- 09By End UserPharmaceutical and Biotechnology Companies · Contract Research and Manufacturing Organizations · Diagnostic Laboratories and Hospitals
- 10By Distribution ChannelDirect Sales · Distributors · Online and E-Commerce
- 11By Region
Market Analysis & Outlook
Culture media are nutrient formulations that let bacteria, fungi, mammalian cells and other organisms grow outside their natural environment. They are supplied as dehydrated powders, ready-to-use liquids, gels, supplements and additives, sera and custom blends, and they serve microbiology testing as well as biologics and cell therapy production. Buyers include biopharmaceutical manufacturers, contract research and manufacturing organizations, diagnostic laboratories, food producers and research institutions.
USD 7.2 billion of revenue was recorded in the global culture media market in 2025. By 2034 the figure reaches USD 14.62 billion, a compound annual growth rate of 8.1% through the forecast period, along a series that runs USD 5 billion in 2020, USD 6.78 billion in 2024, USD 7.84 billion in 2026 and USD 10.84 billion in 2030.
On the product type axis, growth rates run from 4.41% for Sera up to 13.63% for Custom Media. Media Supplements and Additives carries the volume: USD 1.94 billion and 27% of revenue in 2025, USD 4.09 billion and 28% in 2034. The lines gaining share are Ready-to-Use Media, Media Supplements and Additives and Custom Media. Dehydrated Culture Media and Sera lose share without losing revenue.
By formulation, Serum-Free Media accounts for 28% of 2025 revenue at USD 2.02 billion, reaching USD 4.39 billion and 30% by 2034. Chemically Defined Media grows faster at 12.03% against 9.01%, moving from 22% of revenue to 30% by 2034. This axis divides the same revenue as the product type split instead of adding to it, so the two are read together and never summed.
The regional order runs from North America at 34% of 2025 revenue down to Middle East and Africa at 4.5%. North America is worth USD 2.45 billion in 2025 and USD 4.53 billion in 2034; Asia Pacific, second at 29%, moves from USD 2.09 billion to USD 5.12 billion. Share shifts toward Asia Pacific over the forecast period, so the regional split repays a close reading.
Coverage extends to five regions, five product type lines and ten segmentation axes over the full fifteen years. The 2025 total itself is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- Revenue grows from USD 7.2 billion in 2025 to USD 14.62 billion in 2034, a compound annual rate of 8.1%, having reached USD 6.78 billion in 2024 from USD 5 billion in 2020.
- Media Supplements and Additives is the largest product type line at USD 1.94 billion in 2025, a 27% share, reaching USD 4.09 billion and 28% of revenue by 2034.
- At 13.63%, Custom Media grows faster than any other product type line, moving from USD 0.86 billion and 12% of revenue in 2025 to USD 2.78 billion and 19% in 2034.
- The bull case puts 2034 revenue at USD 17.3 billion and the bear case at USD 12.65 billion, either side of the USD 14.62 billion base case, each with its own stated assumption in the full report.
- 34% of 2025 revenue is generated in North America, worth USD 2.45 billion and rising to USD 4.53 billion by 2034; Middle East and Africa is smallest at 4.5%.
- The United States accounts for 87.76% of North America in the base year, worth USD 2.15 billion in 2025 and reaching USD 3.95 billion by 2034, the worked country example carried through that region's chapters.
- Every line on all ten segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.
Market Trends
Revenue Share, By product type
Base year 2025Media Supplements and Additives leads with 27.0% of product type segment revenue.
Share of product type segment revenue, most recent base year.
The global culture media market is shaped over 2026-2034 by three measurable movements: a change in the product type mix, a shift in where revenue sits geographically, and the 8.1% rate carrying the total.
Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.
The product type mix tilts toward Custom Media. The widest spread on the product type axis is between Custom Media at 13.63% and Sera at 4.41%. Shares follow: 12% to 19% for Custom Media, 15% to 11% for Sera. Revenue rises on both sides; USD 0.86 billion to USD 2.78 billion and USD 1.08 billion to USD 1.61 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.
Regional weight shifts toward Asia Pacific. Asia Pacific moves from 29% of revenue in 2025 to 35% in 2034, worth USD 2.09 billion rising to USD 5.12 billion. Against that, North America at 34% moving to 31%, Europe at 26% moving to 23%, Latin America at 6.5% moving to 6.5%, Middle East and Africa at 4.5% moving to 4.5%, a fall in share, not in revenue. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.
Growth compounds at 8.1% without a step change. Year by year the total runs USD 5 billion in 2020, USD 6.78 billion in 2024, USD 7.2 billion in 2025, USD 7.84 billion in 2026, USD 10.84 billion in 2030 and USD 14.62 billion in 2034. Against 7.57% through the historical period, the 8.1% forecast rate is a continuation; no year in the series interrupts it. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the product type and regional axes, not by the headline rate.
Market Growth Factors
Custom Media adds the most incremental growth
Market Drivers
3- 01Custom Media adds the most incremental growth
At 13.63% against a market rate of 8.1%, Custom Media is the line pulling the average up: USD 0.86 billion to USD 2.78 billion, and 12% of revenue to 19%. The market's overall 8.1% depends on that rate holding: at the 4.41% recorded by Sera, the same revenue base would compound to a materially smaller 2034 total. That makes position on the product type axis a growth decision, not a product one.
- 02Regional weight, not regional count
North America is the largest region at USD 2.45 billion in 2025, 34% of global revenue, and reaches USD 4.53 billion by 2034 while holding 31%. Asia Pacific adds a further 29% at USD 2.09 billion, reaching USD 5.12 billion. Most of the base and most of the growth sit in those two, and a plan spread evenly across regions therefore over-invests outside them.
- 03Fifteen years of unbroken growth underpin the forecast
The historical period compounded at 7.57%; USD 5 billion in 2020, USD 6.78 billion in 2024 and USD 7.2 billion in 2025. From there the forecast carries 8.1% through to USD 14.62 billion in 2034. With the trajectory already demonstrated over fifteen years, what remains uncertain is the mix, not the direction, which is where the segment and regional sections do the work.
Growth drivers
| # | Growth driver | Impact | Gross contribution (USD Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Biologics manufacturing expansion | High | +3.1 | High | High | Medium |
| 2 | Cell and gene therapy scale-up | High | +1.9 | Medium | High | High |
| 3 | Shift to serum-free and chemically defined formulations | Medium-High | +1.55 | High | Medium | Medium |
| 4 | Adoption of ready-to-use and single-use formats | Medium-High | +1.2 | Medium | High | Medium |
| 5 | Diagnostic, food and quality control testing volumes | Medium | +1.05 | Medium | Medium | Low |
| 6 | Others | Low | +0.62 | Low | Low | Low |
| Total | +9.42 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (USD Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Volatility in serum, amino acid and growth factor supply and cost | Medium-High | −0.85 | High | Medium | Medium |
| 2 | Validation and requalification effort when media change | Medium | −0.65 | Medium | Medium | Medium |
| 3 | Price pressure from private-label and low-cost dehydrated supply | Medium | −0.5 | Medium | Medium | Low |
| Total | −2 | |||||
Drivers contribute 9.42 USD Billion and restraints remove 2 USD Billion, a net 7.42 USD Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
The 8.1% forecast rate rests on three things that can be measured separately: the size of the existing base, the mix shift on the product type axis, and where regional growth is concentrated.
Restraining Factors
Downside case: USD 12.65 billion by 2034, against USD 14.62 billion in the base case
Market Restraints
2- 01Downside case: USD 12.65 billion by 2034, against USD 14.62 billion in the base case
The study's downside path assumes cell therapy approvals slip, raw material costs stay high and customers delay media changes because of requalification effort, slowing growth in the advanced segments, and ends 2034 at USD 12.65 billion against the USD 14.62 billion base case, the same USD 7.2 billion base year, a slower forecast period.
- 02The largest line is not the fastest
Dehydrated Culture Media carries 24% of 2025 revenue at USD 1.73 billion but compounds at 4.64% against 8.1% for the market, taking its share to 18% by 2034 even as revenue rises to USD 2.63 billion. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it.
Market Opportunities
Upside case: USD 17.3 billion by 2034
Market Opportunities
2- 01Upside case: USD 17.3 billion by 2034
A bull case of USD 17.3 billion by 2034, against USD 14.62 billion in the base case, turns on a single stated assumption: biologics and cell therapy pipelines reach commercial scale sooner, serum-free adoption accelerates and single-use bag uptake spreads faster in Asia Pacific. The USD 7.2 billion 2025 base is common to both.
- 02Custom Media is where share changes hands
Custom Media grows at 13.63% against 8.1% for the market, adding revenue from USD 0.86 billion in 2025 to USD 2.78 billion in 2034 and taking its share from 12% to 19%. It is the place on this axis where share changes hands at scale, so it is where an entrant can take position without displacing the incumbent in Media Supplements and Additives.
Market Challenges
The total depends on a single line
Market Challenges
2- 01The total depends on a single line
USD 1.94 billion of 2025 revenue sits in Media Supplements and Additives, 27% of the total, and it is still 28% at USD 4.09 billion nine years later. A market leaning this heavily on one product type line concentrates its exposure there, and a shift in demand for that line moves the total more than any other single change on the axis.
- 02North America is largely the United States
North America is worth USD 2.45 billion in 2025 and USD 2.15 billion of that is the United States; 87.76% of the region, reaching USD 3.95 billion in 2034. The consequence is that regional risk here is really country risk wearing a larger label.
Segmentation Analysis
10 axesThe market is divided by product type and by formulation, application, cell and organism type, physical form, media function, packaging format, production scale, end user and distribution channel; ten axes in all. They are alternative readings of one revenue pool, not parts that sum to it.
All five product type lines expand in revenue terms over the forecast period. Share is the dividing line; three take it, the others cede it.
By Product Type · 5 segments
Media Supplements and Additives Led by Product type in 2025, with Custom Media Growing Fastest
- Largest Media Supplements and Additives · 27%
- Fastest Custom Media · 13.6%
- Moves most Custom Media · +7 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Dehydrated Culture Media | $1.73B | 24% | $2.63B | 18%-6 | 4.6% |
| Ready-to-Use Media | $1.58B | 22% | $3.51B | 24%+2 | 9.2% |
| Media Supplements and Additives | $1.94B | 27% | $4.09B | 28%+1 | 8.5% |
| Sera | $1.08B | 15% | $1.61B | 11%-4 | 4.4% |
| Custom Media | $0.86B | 12% | $2.78B | 19%+7 | 13.6% |
Supplements and additives lead because every serum-free and chemically defined process needs them in each batch, and their formulation is where suppliers hold the most pricing room. Custom media grows fastest as biologics and cell therapy developers commission formulations tuned to one cell line, which lifts volumes and ties customers to a single supplier through scale-up. Media Supplements and Additives remains the largest line through 2034, so the axis changes in proportion, not in order. Every year of the series is priced on this axis, making it the reference cut for the rest of the report.
By Formulation · 5 segments
Serum-Free Media Held the Dominant Share of the Formulation Segment in 2025
- Largest Serum-Free Media · 28%
- Fastest Chemically Defined Media · 12%
- Moves most Serum-Containing Media · -8 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Serum-Containing Media | $1.44B | 20% | $1.75B | 12%-8 | 2.2% |
| Serum-Free Media | $2.02B | 28% | $4.39B | 30%+2 | 9% |
| Chemically Defined Media | $1.58B | 22% | $4.39B | 30%+8 | 12% |
| Protein-Free Media | $0.58B | 8% | $1.02B | 7%-1 | 6.5% |
| Animal-Origin-Free Media | $1.58B | 22% | $3.07B | 21%-1 | 7.7% |
Serum-free media lead because regulators and biologics makers prefer defined, reproducible inputs over animal-derived serum with lot variability. Chemically defined media grows fastest as manufacturers lock in compositions that carry cleanly from development into commercial production, and as safety expectations for therapies push out undefined components. Serum-Free Media remains the largest line through 2034, so the axis changes in proportion, not in order.
By Application · 7 segments
By Application
- Largest Biopharmaceutical Production · 34%
- Fastest Cell and Gene Therapy · 17.6%
- Moves most Cell and Gene Therapy · +9 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Biopharmaceutical Production | $2.45B | 34% | $5.26B | 36%+2 | 8.9% |
| Cell and Gene Therapy | $0.58B | 8% | $2.49B | 17%+9 | 17.6% |
| Clinical Microbiology Diagnostics | $1.58B | 22% | $2.19B | 15%-7 | 3.7% |
| Pharmaceutical Quality Control | $1.01B | 14% | $1.75B | 12%-2 | 6.3% |
| Food and Beverage Safety Testing | $0.72B | 10% | $1.17B | 8%-2 | 5.5% |
| Environmental and Water Testing | $0.29B | 4% | $0.44B | 3%-1 | 4.7% |
| Academic and Basic Research | $0.58B | 8% | $1.32B | 9%+1 | 9.6% |
2025 to 2034 revenue and share by line: Biopharmaceutical Production USD 2.45 billion to USD 5.26 billion (34% to 36%), Clinical Microbiology Diagnostics USD 1.58 billion to USD 2.19 billion (22% to 15%), Pharmaceutical Quality Control USD 1.01 billion to USD 1.75 billion (14% to 12%), Food and Beverage Safety Testing USD 0.72 billion to USD 1.17 billion (10% to 8%), Cell and Gene Therapy USD 0.58 billion to USD 2.49 billion (8% to 17%), Academic and Basic Research USD 0.58 billion to USD 1.32 billion (8% to 9%), Environmental and Water Testing USD 0.29 billion to USD 0.44 billion (4% to 3%). Scale in Biopharmaceutical Production and Growth in Cell and Gene Therapy Define the Application Axis Biopharmaceutical production leads because large-volume culture for antibodies and recombinant proteins consumes the most media per site. Cell and gene therapy grows fastest as more candidates move into clinical and commercial manufacture, each needing specialised, tightly controlled media in small but high-value batches. By 2034 Biopharmaceutical Production is still ahead, making this a shift in weight, not a change of leader.
By Cell and Organism Type · 6 segments
Mammalian Held the Dominant Share of the Cell and organism type Segment in 2025
- Largest Mammalian · 42%
- Fastest Stem Cells · 10.9%
- Moves most Bacterial · -8 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Bacterial | $2.16B | 30% | $3.22B | 22%-8 | 4.5% |
| Fungal and Yeast | $0.58B | 8% | $0.88B | 6%-2 | 4.7% |
| Mammalian | $3.02B | 42% | $7.24B | 49.5%+7.5 | 10.2% |
| Insect | $0.29B | 4% | $0.73B | 5%+1 | 10.8% |
| Stem Cells | $0.86B | 12% | $2.19B | 15%+3 | 10.9% |
| Plant and Algae | $0.29B | 4% | $0.37B | 2.5%-1.5 | 2.7% |
Mammalian cell lines lead because antibody and protein production runs on them, and their media is more complex and costly than microbial broths. Stem cells grow fastest as regenerative and cell therapy programmes expand and need tailored expansion and differentiation media. By 2034 Mammalian is still ahead, making this a shift in weight, not a change of leader.
By Physical Form · 4 segments
Scale and Growth Sit in the Same Line on the Physical form Axis: Liquid
- Largest Liquid · 50%
- Fastest Liquid · 10.4%
- Moves most Liquid · +10 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Powder | $2.59B | 36% | $3.95B | 27%-9 | 4.8% |
| Liquid | $3.60B | 50% | $8.77B | 60%+10 | 10.4% |
| Semi-Solid Gel | $0.58B | 8% | $0.88B | 6%-2 | 4.7% |
| Lyophilized and Tablet | $0.43B | 6% | $1.02B | 7%+1 | 10.1% |
Liquid media leads because ready-made solutions save preparation time and cut contamination risk in regulated sites. Lyophilized and tablet formats grow fastest as users seek longer shelf life and easier shipping to remote or decentralised laboratories, while powder keeps a base among cost-sensitive microbiology buyers. Liquid remains the largest line through 2034, so the axis changes in proportion, not in order.
By Media Function · 6 segments
Scale and Growth Sit in the Same Line on the Media function Axis: General-Purpose
- Largest General-Purpose · 46%
- Fastest General-Purpose · 10.6%
- Moves most General-Purpose · +10 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| General-Purpose | $3.31B | 46% | $8.19B | 56%+10 | 10.6% |
| Selective | $1.30B | 18% | $1.90B | 13%-5 | 4.3% |
| Differential | $0.72B | 10% | $1.17B | 8%-2 | 5.5% |
| Enrichment | $0.72B | 10% | $1.17B | 8%-2 | 5.5% |
| Chromogenic | $0.72B | 10% | $1.61B | 11%+1 | 9.3% |
| Transport | $0.43B | 6% | $0.58B | 4%-2 | 3.4% |
General-purpose media lead because bioprocess and routine culture use broad growth formulations in the greatest volume. Chromogenic media grows fastest as laboratories replace multi-step identification with colour-coded plates that speed pathogen detection and reduce manual confirmation work in food and clinical testing. By 2034 General-Purpose is still ahead, making this a shift in weight, not a change of leader.
By Packaging Format · 5 segments
Bottles Led by Packaging format in 2025, with Bags and Bioprocess Containers Growing Fastest
- Largest Bottles · 36%
- Fastest Bags and Bioprocess Containers · 16.9%
- Moves most Bags and Bioprocess Containers · +12 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Petri Plates | $1.44B | 20% | $2.05B | 14%-6 | 4% |
| Tubes and Vials | $1.01B | 14% | $1.61B | 11%-3 | 5.3% |
| Bottles | $2.59B | 36% | $4.82B | 33%-3 | 7.2% |
| Bags and Bioprocess Containers | $0.86B | 12% | $3.51B | 24%+12 | 16.9% |
| Bulk Drums and Sacks | $1.30B | 18% | $2.63B | 18% | 8.1% |
Bottles lead because liquid media is most often supplied in standard laboratory and pilot-scale volumes. Bags and bioprocess containers grow fastest as single-use manufacturing spreads, since pre-sterilised bags remove cleaning validation and connect directly to disposable bioreactor systems in biologics plants. Bottles remains the largest line through 2034, so the axis changes in proportion, not in order.
By Production Scale · 3 segments
Scale and Growth Sit in the Same Line on the Production scale Axis: Commercial Manufacturing Scale
- Largest Commercial Manufacturing Scale · 48%
- Fastest Commercial Manufacturing Scale · 9.4%
- Moves most Research Scale · -5 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Research Scale | $1.58B | 22% | $2.49B | 17%-5 | 5.2% |
| Process Development Scale | $2.16B | 30% | $4.39B | 30% | 8.2% |
| Commercial Manufacturing Scale | $3.46B | 48% | $7.75B | 53%+5 | 9.4% |
Commercial manufacturing scale leads because each licensed product draws media in large recurring volumes for its whole lifecycle. The same scale also grows fastest, as approved biologics and early cell therapies move from pilot lots into routine supply and as process development work feeds the pipeline behind them. Commercial Manufacturing Scale remains the largest line through 2034, so the axis changes in proportion, not in order.
By End User · 5 segments
Pharmaceutical and Biotechnology Companies Led by End user in 2025, with Contract Research and Manufacturing Organizations Growing Fastest
- Largest Pharmaceutical and Biotechnology Companies · 40%
- Fastest Contract Research and Manufacturing Organizations · 11.8%
- Moves most Diagnostic Laboratories and Hospitals · -6 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Pharmaceutical and Biotechnology Companies | $2.88B | 40% | $6.43B | 44%+4 | 9.3% |
| Contract Research and Manufacturing Organizations | $0.86B | 12% | $2.34B | 16%+4 | 11.8% |
| Diagnostic Laboratories and Hospitals | $1.73B | 24% | $2.63B | 18%-6 | 4.8% |
| Food and Beverage Manufacturers | $0.86B | 12% | $1.32B | 9%-3 | 4.9% |
| Academic and Research Institutes | $0.86B | 12% | $1.90B | 13%+1 | 9.2% |
Pharmaceutical and biotechnology companies lead because they run the largest culture operations and buy qualified media under supply agreements. Contract research and manufacturing organizations grow fastest as sponsors outsource development and clinical production, concentrating media purchasing in fewer, larger accounts that buy in volume. Pharmaceutical and Biotechnology Companies remains the largest line through 2034, so the axis changes in proportion, not in order.
By Distribution Channel · 3 segments
Online and E-Commerce Outpaces the Axis While Direct Sales Holds the Largest Share
- Largest Direct Sales · 55%
- Fastest Online and E-Commerce · 11.4%
- Moves most Distributors · -4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Direct Sales | $3.96B | 55% | $8.33B | 57%+2 | 8.6% |
| Distributors | $2.74B | 38% | $4.97B | 34%-4 | 6.8% |
| Online and E-Commerce | $0.50B | 7% | $1.32B | 9%+2 | 11.4% |
Direct sales lead because large buyers need technical support, quality agreements and consistent lots that suppliers handle themselves. Online channels grow fastest as smaller laboratories reorder standard catalogue media through web platforms, with faster quotation and delivery than a distributor visit provides. The order does not change: Direct Sales is still largest in 2034, and what moves is how much it holds.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The largest region covered — 3 points of share move elsewhere by 2034, while revenue still grows 1.8×.
- Rank 1 of 5
- 2025 share 34%
- By 2034 31%
- Revenue $2.45B → $4.53B
34% of the global culture media market sits in North America in 2025, worth USD 2.45 billion rising to USD 4.53 billion in 2034. That makes it the first-largest region covered, in 2025 and again in 2034.
Share settles at 31% in 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Segment composition follows the global pattern: Media Supplements and Additives largest at 27% of 2025 revenue, Custom Media fastest at 13.63%. North America is reported axis by axis and country by country in the full study.
United States
Sets the pace for North America at 87.8% of it, growing 1.8×.
- In region 1 of 2
- Of region 87.8%
- Of global 29.9%
- Revenue $2.15B → $3.95B
87.76% of North America's base-year revenue comes from the United States; USD 2.15 billion, rising to USD 3.95 billion by 2034. 87.76% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. Against regional totals of USD 2.45 billion in 2025 and USD 4.53 billion in 2034, it is the country the full report breaks out in detail.
The product type pattern in the United States is the global one: 27% of 2025 revenue in Media Supplements and Additives, 28% by 2034, against 13.63% growth in Custom Media taking it from 12% to 19%. Its 87.76% weight in North America means those movements carry straight into the regional totals. The full report reports the United States by product type separately.
Culture media sold in the United States fall under the Food and Drug Administration, and the route depends on intended use. Media for research and general laboratory work are generally treated as laboratory reagents without premarket review. Media labelled for diagnostic use, such as isolating pathogens from clinical specimens, are regulated as in vitro diagnostic devices, usually in a lower risk class that is exempt from premarket notification or cleared through that process. Suppliers must register their establishment, list their products and follow the quality system regulation. Labelling must state intended use, storage and expiry, and research-only products must carry the research-use-only statement. Clinical laboratories using the media are separately governed by the Clinical Laboratory Improvement Amendments.
In the United States the field is Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Becton, Dickinson and Company, bioMérieux SA, Sartorius AG, Lonza Group AG, Corning Incorporated, FUJIFILM Holdings Corporation, Neogen Corporation, HiMedia Laboratories Pvt. Ltd., Hardy Diagnostics, Liofilchem S.r.l., Solabia Group, Eiken Chemical Co., Ltd., Nissui Pharmaceutical Co., Ltd., Kerry Group plc, PromoCell GmbH, STEMCELL Technologies Inc., Takara Bio Inc., Bio-Techne Corporation, Avantor, Inc., Biolife Italiana S.r.l., Scharlab S.L. and Mast Group Ltd.. The commercially relevant division is 27% of 2025 revenue in Media Supplements and Additives, where the volume is, against 13.63% growth in Custom Media, where share moves. Country-level shares and positioning per company sit in the full report.
Canada
2nd-largest in North America, growing 1.9×.
- In region 2 of 2
- Of region 8.2%
- Of global 2.8%
- Revenue $0.20B → $0.38B
Canada is sized at USD 0.2 billion in 2025, rising to USD 0.38 billion by 2034; 2.78% of global revenue and 8.16% of North America. It is reported separately from the United States across every segmentation axis in the full report.
Europe Market Analysis
The 3rd-largest region covered — 3 points of share move elsewhere by 2034, while revenue still grows 1.8×.
- Rank 3 of 5
- 2025 share 26%
- By 2034 23%
- Revenue $1.87B → $3.36B
USD 1.87 billion of 2025 revenue is generated in Europe, 26% of the global culture media market on the way to USD 3.36 billion by 2034. By revenue it sits third across the study, and the ranking does not change between 2025 and 2034.
Share settles at 23% in 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Segment composition follows the global pattern: Media Supplements and Additives largest at 27% of 2025 revenue, Custom Media fastest at 13.63%. Europe is reported axis by axis and country by country in the full study.
Germany
The largest market in Europe, growing 1.8×.
- In region 1 of 3
- Of region 26.7%
- Of global 6.9%
- Revenue $0.50B → $0.88B
Germany is the largest market within Europe, generating USD 0.5 billion in 2025 and projected to reach USD 0.88 billion by 2034. 26.74% of the region in the base year makes it the largest market here without making it the region. Set against USD 1.87 billion and USD 3.36 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
Germany buys along the same lines as the market globally; Media Supplements and Additives first at 27% of 2025 revenue and 28% in 2034, Custom Media fastest at 13.63% on a share moving from 12% to 19%. Because the country carries 26.74% of Europe, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Revenue by product type for Germany is reported separately in the full report.
In Germany, culture media for diagnostic purposes are in vitro diagnostic medical devices under the EU In Vitro Diagnostic Medical Devices Regulation, which replaced the earlier directive. Most microbiological media sit in the lowest risk class and are self-certified by the manufacturer, who draws up technical documentation, applies a quality management system and affixes the CE mark. Higher classes involve a notified body. The Federal Institute for Drugs and Medical Devices oversees vigilance and market surveillance alongside the state authorities. Labelling must give intended purpose, storage conditions, expiry and a unique device identifier, in German for professional users. Media for research use fall outside this regime, though chemical safety labelling still applies.
In Germany the field is Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Becton, Dickinson and Company, bioMérieux SA, Sartorius AG, Lonza Group AG, Corning Incorporated, FUJIFILM Holdings Corporation, Neogen Corporation, HiMedia Laboratories Pvt. Ltd., Hardy Diagnostics, Liofilchem S.r.l., Solabia Group, Eiken Chemical Co., Ltd., Nissui Pharmaceutical Co., Ltd., Kerry Group plc, PromoCell GmbH, STEMCELL Technologies Inc., Takara Bio Inc., Bio-Techne Corporation, Avantor, Inc., Biolife Italiana S.r.l., Scharlab S.L. and Mast Group Ltd.. Two different problems sit on the same axis: holding Media Supplements and Additives at 27% of 2025 revenue, and taking Custom Media while it grows at 13.63%. A supplier weighted toward Europe is competing over a base of USD 1.87 billion in 2025, reaching USD 3.36 billion by 2034 on the trajectory this study models.
United Kingdom
2nd-largest in Europe, growing 1.8×.
- In region 2 of 3
- Of region 18.2%
- Of global 4.7%
- Revenue $0.34B → $0.60B
Within Europe, the United Kingdom accounts for 18.18% of regional revenue and 4.72% of the global total, worth USD 0.34 billion in 2025 and USD 0.6 billion by 2034.
France
3rd-largest in Europe, growing 1.8×.
- In region 3 of 3
- Of region 13.9%
- Of global 3.6%
- Revenue $0.26B → $0.46B
Within Europe, France accounts for 13.9% of regional revenue and 3.61% of the global total, worth USD 0.26 billion in 2025 and USD 0.46 billion by 2034.
Asia Pacific Market Analysis
The 2nd-largest region covered, and the one gaining the most — it picks up 6 points of share by 2034, while revenue still grows 2.4×.
- Rank 2 of 5
- 2025 share 29%
- By 2034 35%
- Revenue $2.09B → $5.12B
Asia Pacific holds 29% of the global culture media market in 2025, worth USD 2.09 billion and reaches USD 5.12 billion by 2034. It is a leading region on this axis, second by revenue throughout the period.
Share climbs to 35% by 2034, at a pace above the 8.1% global rate, so this region warrants separate treatment and should not be scaled off the total.
Segment composition follows the global pattern: Media Supplements and Additives largest at 27% of 2025 revenue, Custom Media fastest at 13.63%. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.
China
The largest market in Asia Pacific, growing 2.6×.
- In region 1 of 3
- Of region 37.3%
- Of global 10.8%
- Revenue $0.78B → $2.05B
The largest single market in Asia Pacific is China, at USD 0.78 billion in 2025 and USD 2.05 billion in 2034. 37.32% of the region in the base year makes it the largest market here without making it the region. Against regional totals of USD 2.09 billion in 2025 and USD 5.12 billion in 2034, it is the country the full report breaks out in detail.
Composition here matches the global split: the largest line is Media Supplements and Additives at 27% of 2025 revenue, easing to 28% by 2034, and the fastest is Custom Media at 13.63%, from 12% to 19%. Since 37.32% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. The full report reports China by product type separately.
In China, culture media used for diagnosis are regulated as medical devices by the National Medical Products Administration. Microbial culture media for clinical use are generally placed in a low-risk class, which requires filing with the provincial or municipal drug regulator, while media for specific diagnostic claims may need full registration with product testing and technical review. Domestic manufacturers also need a production licence and must follow the medical device good manufacturing practice. Imported products need a local legal agent and registration before sale. Labelling and instructions must be in Chinese and state intended use, storage and shelf life. Media for biopharmaceutical production are governed through the pharmaceutical quality rules of the end user.
In China the field is Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Becton, Dickinson and Company, bioMérieux SA, Sartorius AG, Lonza Group AG, Corning Incorporated, FUJIFILM Holdings Corporation, Neogen Corporation, HiMedia Laboratories Pvt. Ltd., Hardy Diagnostics, Liofilchem S.r.l., Solabia Group, Eiken Chemical Co., Ltd., Nissui Pharmaceutical Co., Ltd., Kerry Group plc, PromoCell GmbH, STEMCELL Technologies Inc., Takara Bio Inc., Bio-Techne Corporation, Avantor, Inc., Biolife Italiana S.r.l., Scharlab S.L. and Mast Group Ltd.. The commercially relevant division is 27% of 2025 revenue in Media Supplements and Additives, where the volume is, against 13.63% growth in Custom Media, where share moves. The commercial size of that position is USD 2.09 billion in 2025 and USD 5.12 billion by 2034, 29% of the global total in the base year.
Japan
2nd-largest in Asia Pacific, growing 1.7×.
- In region 2 of 3
- Of region 21.5%
- Of global 6.3%
- Revenue $0.45B → $0.78B
6.25% of global revenue is generated in Japan; USD 0.45 billion in 2025, reaching USD 0.78 billion in 2034, and 21.53% of Asia Pacific.
India
3rd-largest in Asia Pacific, growing 2.8×.
- In region 3 of 3
- Of region 10.5%
- Of global 3.1%
- Revenue $0.22B → $0.62B
3.06% of global revenue is generated in India; USD 0.22 billion in 2025, reaching USD 0.62 billion in 2034, and 10.53% of Asia Pacific.
Latin America Market Analysis
The 4th-largest region covered, holding its share flat through 2034, while revenue still grows 2.0×.
- Rank 4 of 5
- 2025 share 6.5%
- By 2034 6.5%
- Revenue $0.47B → $0.95B
Latin America holds 6.5% of the global culture media market in 2025, worth USD 0.47 billion on the way to USD 0.95 billion by 2034. It is a marginal region on this axis, fourth by revenue throughout the period.
6.5% of global revenue sits here in 2034, below the 2025 level, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
Within the region the product type split tracks the global one; 27% of 2025 revenue in Media Supplements and Additives, fastest growth of 13.63% in Custom Media. The full report breaks Latin America out along every axis and by country.
Brazil
The largest market in Latin America, growing 2.0×.
- In region 1 of 2
- Of region 46.8%
- Of global 3.1%
- Revenue $0.22B → $0.45B
USD 0.22 billion of Latin America's 2025 revenue is generated in Brazil, the region's largest market, reaching USD 0.45 billion by 2034. At 46.81% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. Set against USD 0.47 billion and USD 0.95 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
Composition here matches the global split: the largest line is Media Supplements and Additives at 27% of 2025 revenue, easing to 28% by 2034, and the fastest is Custom Media at 13.63%, from 12% to 19%. Its 46.81% weight in Latin America means those movements carry straight into the regional totals. Revenue by product type for Brazil is reported separately in the full report.
In Brazil, culture media intended for diagnostic use are regulated as in vitro diagnostic products by the National Health Surveillance Agency, known as ANVISA. Products are classified by risk, and lower-risk classes are generally handled through a notification route, while higher-risk classes require full registration with technical dossiers. Manufacturers and importers need an operating authorisation and must comply with the agency's good manufacturing practice for health products; foreign suppliers rely on a local registration holder. Labels and instructions for use must be in Portuguese and state intended use, storage and expiry. Media sold only for research or industrial uses largely fall outside this route, though import controls and general chemical safety rules still apply.
In Brazil the field is Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Becton, Dickinson and Company, bioMérieux SA, Sartorius AG, Lonza Group AG, Corning Incorporated, FUJIFILM Holdings Corporation, Neogen Corporation, HiMedia Laboratories Pvt. Ltd., Hardy Diagnostics, Liofilchem S.r.l., Solabia Group, Eiken Chemical Co., Ltd., Nissui Pharmaceutical Co., Ltd., Kerry Group plc, PromoCell GmbH, STEMCELL Technologies Inc., Takara Bio Inc., Bio-Techne Corporation, Avantor, Inc., Biolife Italiana S.r.l., Scharlab S.L. and Mast Group Ltd.. Two different problems sit on the same axis: holding Media Supplements and Additives at 27% of 2025 revenue, and taking Custom Media while it grows at 13.63%. A supplier weighted toward Latin America is competing over a base of USD 0.47 billion in 2025 reaching USD 0.95 billion by 2034, 6.5% of global revenue at the start of that period.
Mexico
2nd-largest in Latin America, growing 2.0×.
- In region 2 of 2
- Of region 21.3%
- Of global 1.4%
- Revenue $0.10B → $0.20B
1.39% of global revenue is generated in Mexico; USD 0.1 billion in 2025, reaching USD 0.2 billion in 2034, and 21.28% of Latin America.
Middle East and Africa Market Analysis
The 5th-largest region covered, holding its share flat through 2034, while revenue still grows 2.1×.
- Rank 5 of 5
- 2025 share 4.5%
- By 2034 4.5%
- Revenue $0.32B → $0.66B
In Middle East and Africa, 4.5% of global revenue puts 2025 at USD 0.32 billion on the way to USD 0.66 billion by 2034. Among the five regions it ranks fifth by revenue in both years.
By 2034 the share stands at 4.5%, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
Media Supplements and Additives leads here as it does globally, at 27% of 2025 revenue, and Custom Media again grows fastest at 13.63%. The full report breaks Middle East and Africa out along every axis and by country.
Saudi Arabia
The largest market in Middle East and Africa, growing 2.2×.
- In region 1 of 2
- Of region 18.8%
- Of global 0.8%
- Revenue $0.06B → $0.13B
Saudi Arabia is the largest market within Middle East and Africa, generating USD 0.06 billion in 2025 and projected to reach USD 0.13 billion by 2034. It accounts for 18.75% of regional revenue in the base year, the largest single share without dominating the region outright. The region itself runs USD 0.32 billion to USD 0.66 billion over the same period, and this is the market carrying the country-level detail in the full report.
Demand in Saudi Arabia follows the product type mix reported at global level: Media Supplements and Additives is the largest line at 27% of 2025 revenue, moving to 28% by 2034, while Custom Media grows fastest at 13.63% and takes its share from 12% to 19%. Since 18.75% of Middle East and Africa's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. The full report reports Saudi Arabia by product type separately.
In Saudi Arabia, the Saudi Food and Drug Authority regulates culture media intended for diagnostic use as in vitro diagnostic medical devices. Manufacturers outside the country must appoint an authorised representative holding a licence, and products require marketing authorisation before sale, supported by technical documentation and evidence of approval in a recognised jurisdiction or conformity with international standards. Establishments are licensed, and post-market reporting of incidents is expected. Labelling must give intended use, storage conditions and expiry, with Arabic and English information for users. Research-use media face lighter controls, though imports still pass through customs and the authority's shipment clearance procedures.
In Saudi Arabia the field is Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Becton, Dickinson and Company, bioMérieux SA, Sartorius AG, Lonza Group AG, Corning Incorporated, FUJIFILM Holdings Corporation, Neogen Corporation, HiMedia Laboratories Pvt. Ltd., Hardy Diagnostics, Liofilchem S.r.l., Solabia Group, Eiken Chemical Co., Ltd., Nissui Pharmaceutical Co., Ltd., Kerry Group plc, PromoCell GmbH, STEMCELL Technologies Inc., Takara Bio Inc., Bio-Techne Corporation, Avantor, Inc., Biolife Italiana S.r.l., Scharlab S.L. and Mast Group Ltd.. Two different problems sit on the same axis: holding Media Supplements and Additives at 27% of 2025 revenue, and taking Custom Media while it grows at 13.63%. A supplier weighted toward Middle East and Africa is competing over a base of USD 0.32 billion in 2025, reaching USD 0.66 billion by 2034 on the trajectory this study models.
South Africa
2nd-largest in Middle East and Africa, growing 1.8×.
- In region 2 of 2
- Of region 15.6%
- Of global 0.7%
- Revenue $0.05B → $0.09B
0.69% of global revenue is generated in South Africa; USD 0.05 billion in 2025, reaching USD 0.09 billion in 2034, and 15.63% of Middle East and Africa.
Download a free sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by product type, formulation, application, cell and organism type, physical form, media function, packaging format, production scale, end user, distribution channel, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Suppliers Compete on Media Supplements and Additives Volume and Custom Media Momentum
The field covered here is Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Becton, Dickinson and Company, bioMérieux SA, Sartorius AG, Lonza Group AG, Corning Incorporated, FUJIFILM Holdings Corporation, Neogen Corporation, HiMedia Laboratories Pvt. Ltd., Hardy Diagnostics, Liofilchem S.r.l., Solabia Group, Eiken Chemical Co., Ltd., Nissui Pharmaceutical Co., Ltd., Kerry Group plc, PromoCell GmbH, STEMCELL Technologies Inc., Takara Bio Inc., Bio-Techne Corporation, Avantor, Inc., Biolife Italiana S.r.l., Scharlab S.L. and Mast Group Ltd..
Competition follows the product type split, not the regional one. Volume sits in Media Supplements and Additives, USD 1.94 billion and 27% of 2025 revenue, 28% by 2034, which is also where an incumbent is hardest to dislodge. Movement is concentrated in Custom Media; 13.63% growth, against 4.41% at the other end of the axis in Sera. The two rarely sit with the same supplier, and that is the reason a USD 7.2 billion market is not already consolidated.
Scale in formulation and lot-to-lot consistency separates leading suppliers, since regulated buyers qualify a medium once and rarely switch. Large players hold broad catalogues across microbiology and cell culture, regulatory documentation that supports drug master files, and global distribution with technical service teams. Supply reliability for sera, growth factors and amino acids also favours those with long supplier contracts. Smaller and regional firms compete on niche selective and chromogenic plates, local-language support, faster delivery, price in cost-sensitive laboratories and custom formulations built for one cell line. Private-label supply to distributors adds price pressure in standard dehydrated products.
Presence matters unevenly by region. With 34% of 2025 revenue in North America and 29% in Asia Pacific, a supplier's coverage of those two decides most of its addressable base before any product question arises.
Company-level profiles, financials, shares and development histories are held in the full report and not in this summary.
List of Key Culture Media Market Companies Profiled
25 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Thermo Fisher Scientific Inc.(United States)
- Merck KGaA(Germany)
- Danaher Corporation(United States)
- Becton, Dickinson and Company(United States)
- bioMérieux SA(France)
- Sartorius AG(Germany)
- Lonza Group AG(Switzerland)
- Corning Incorporated(United States)
- FUJIFILM Holdings Corporation(Japan)
- Neogen Corporation(United States)
- HiMedia Laboratories Pvt. Ltd.(India)
- Hardy Diagnostics(United States)
- Liofilchem S.r.l.(Italy)
- Solabia Group(France)
- Eiken Chemical Co., Ltd.(Japan)
- Nissui Pharmaceutical Co., Ltd.(Japan)
- Kerry Group plc(Ireland)
- PromoCell GmbH(Germany)
- STEMCELL Technologies Inc.(Canada)
- Takara Bio Inc.(Japan)
- Bio-Techne Corporation(United States)
- Avantor, Inc.(United States)
- Biolife Italiana S.r.l.(Italy)
- Scharlab S.L.(Spain)
- Mast Group Ltd.(United Kingdom)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 10 axes (Product Type, Formulation, Application, Cell and Organism Type, Physical Form, Media Function, Packaging Format, Production Scale, End User, Distribution Channel), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 25 key companies, and the research methodology behind every estimate.
Segmentation
10 axes + regionQuestions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Culture Media Market projected to reach?
USD 14.62 USD Billion by 2034, CAGR 8.1%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 34% of global revenue through 2034.
05Which segment leads the market?
Media Supplements and Additives is the largest line by product type, at 27% of revenue in 2025.
06Who are the key companies profiled?
Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Becton, Dickinson and Company, bioMérieux SA, Sartorius AG, Lonza Group AG, Corning Incorporated, FUJIFILM Holdings Corporation, Neogen Corporation, HiMedia Laboratories Pvt. Ltd., Hardy Diagnostics, Liofilchem S.r.l., Solabia Group, Eiken Chemical Co., Ltd., Nissui Pharmaceutical Co., Ltd., Kerry Group plc, PromoCell GmbH, STEMCELL Technologies Inc., Takara Bio Inc., Bio-Techne Corporation, Avantor, Inc., Biolife Italiana S.r.l., Scharlab S.L., Mast Group Ltd.. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.